Profile: Boehringer’s Andersen On Volleyball And Leadership Learnings, Storytelling
Executive Summary
Boehringer Ingelheim’s Head of Human Pharma Regions, Timmo Rousku Andersen shares with Scrip glimpses of his life and professional journey including distinct parallels between sports and leadership against the backdrop of the wider commercialization efforts for blockbuster therapy Jardiance.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Merck remains confident in TIGIT; Otezla and Sotyktu battle for share in psoriasis; GSK chief warns about worsening UK pharma sector; China plans to ban gene editing technology exports; and an interview with Boehringer Ingelheim’s head of human pharma regions.
Pharma's Clinical Ops Digital Maturity: Patient Experience Tools Lag
Digital maturity of clinical operations at several big pharma firms varies significantly with the gap between best-in-class and the industry average narrowest for site selection tools, recruitment capabilities, and automation, a study has indicated. Digital patient experience tools figure among the least mature capabilities.
Provention Plans Two-Phase Launch Of Tzield, Pricing Drug Higher Than Expected
At nearly $194,000, the wholesale acquisition cost for Tzield came in above analysts’ $100,000-$115,000 estimates, but payer pushback is not expected as the drug faces no competition.